Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 4Phase NA 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 129Terminated 27Unknown 8Withdrawn 6Active not recruiting 4Recruiting 3Suspended 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4CNS 4

Conditions

Breast Neoplasms 186Carcinoma, Non-Small-Cell Lung 144Multiple Myeloma 120Prostatic Neoplasms 118Leukemia, Myeloid, Acute 77Neoplasms 75Colorectal Neoplasms 75Melanoma 72Neoplasm Metastasis 66Lymphoma 66Squamous Cell Carcinoma of Head and Neck 64Lung Neoplasms 64Pancreatic Neoplasms 54Ovarian Neoplasms 50Sarcoma 46Carcinoma, Renal Cell 45Triple Negative Breast Neoplasms 43Glioblastoma 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 38Hematologic Neoplasms 37Lymphoma, Large B-Cell, Diffuse 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Myelodysplastic Syndromes 35Lymphoma, Non-Hodgkin 34Brain Neoplasms 34Lymphoma, Mantle-Cell 31

Interventions

sargramostim 2pembrolizumab 2Temozolomide 2montanide ISA 51 1Sucrose 1Radiotherapy 1Radiation 1Granulocyte-Macrophage Colony-Stimulating Factor 1Cyclophosphamide 1Colony-Stimulating Factors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Gliosarcoma × Clear all
NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Mayo Clinic

Phase 2 Active not recruiting
52 enrolled 19 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02337686 2025-08-15

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
18 enrolled 12 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Epitopoietic Research Corporation

Phase 2 Active not recruiting
84 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡